Alkeus Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.alkeuspharma.com
Clinical Trials
4
Active:1
Completed:2
Trial Phases
3 Phases
Phase 1:1
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (50.0%)Phase 1
1 (25.0%)Phase 3
1 (25.0%)Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
Phase 2
Active, not recruiting
- Conditions
- Stargardt Macular DystrophyAutosomal Recessive Stargardt Disease 1 (ABCA4-related)Stargardt DiseaseStargardt Macular Degeneration
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Alkeus Pharmaceuticals, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04239625
- Locations
- 🇺🇸
Alkeus Site, Silverdale, Washington, United States
Phase 3 Study of ALK-001 in Geographic Atrophy
Phase 3
Completed
- Conditions
- Age Related Macular DegenerationGeographic AtrophyAtrophy, GeographicAMD
- Interventions
- Drug: Placebo oral capsuleDrug: ALK-001 oral capsule
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Alkeus Pharmaceuticals, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03845582
- Locations
- 🇺🇸
Coordinating Center, Somerville, Massachusetts, United States
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Phase 2
- Conditions
- Stargardt Macular DystrophyAutosomal Recessive Stargardt Disease 1 (ABCA4-related)Stargardt DiseaseStargardt Macular Degeneration
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Alkeus Pharmaceuticals, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT02402660
- Locations
- 🇺🇸
Alkeus Site, Milwaukee, Wisconsin, United States
Phase 1 Safety Study of ALK-001 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Stargardt DiseaseAge-related Macular DegenerationOther Retinal Dystrophies
- Interventions
- Drug: ALK-001 (No generic name)
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Alkeus Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02230228
News
No news found